Kosin University Gospel Hospital
Kosin University Gospel Hospital
Busan, South Korea9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2026-09-17 | NCT05418556 | |
| Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy | Arterial Occlusive Diseases, Digestive System Diseases, Gastrointestinal Hemorrhage, Hemorrhage, Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute coronary syndrome, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, digestive system disorder, duodenal disorder, heart disorder, intestinal disorder, ischemic disease, myocardial infarction, myocardial ischemia, peptic ulcer disease, stomach disorder, vascular disorder | Recruiting | Phase 4 | 2026-08-28 | NCT04416581 | |
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-07-14 | NCT02864992 | |
| A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants | Digestive System Diseases, Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, colitis, colonic disorder, connective tissue disorder, digestive system disorder, gastroenteritis, immune system disorder, inflammatory bowel disease, intestinal disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, ulcerative colitis | Recruiting | Not stated | 2026-07-06 | NCT06246123 | |
| Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-01 | NCT03315364 | |
| Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, gastric neoplasm, intestinal disorder, lung disorder, lung neoplasm, microinvasive gastric cancer, neoplasm, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder | Recruiting | Not applicable | 2026-02-12 | NCT07405931 | |
| Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION) | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2025-12-31 | NCT05845489 | |
| NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 2 | 2024-12-17 | NCT06737250 | |
| IRIS-Synergy Cohort in the IRIS-DES Registry | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not stated | 2023-12-18 | NCT02720419 |